Will Mylan's move impact Lupin's revenues? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Will Mylan's move impact Lupin's revenues?

Mar 23, 2013

It is a very well known fact that the entry of a company in any segment or class adds to the competition in the said market. This also results in a pricing war among the companies. The same rule applies to the pharma sector as well. Infact, the price erosion in this segment is much intense and takes place at a faster pace, for a given drug. That's not all. An entry of a new company in this sector for any particular drug weighs heavy on the revenues of the existing company in a much lesser time period in contrast to other sectors.

Something similar is happening to the Indian pharma company Lupin. In a month's time, Mylan has hit two of Lupin's important drugs viz., Fortamet generics and Antara and this will impact the latter's revenues. Let's have a closer look.

Mylan is one of the world's leading generics and specialty pharmaceutical companies, providing products to customers in approximately 150 countries and territories. It has presence in developed and emerging countries. Mylan is the second largest (by volume) generic company in the US.

Mylan's stroke

In February 2013, Mylan launched the generic version of Antara. This launch is most likely an at-risk launch, though there is still not much clarity on this.

The other drug Fortamet too has been targeted by Mylan. Recently, Mylan entered into settlement with the innovator to sell the generic version of Fortamet in the US. As per the settlement (between innovator and Mylan), Mylan will start selling generic Fortamet from August 2013 onwards.

Impact of Mylan's launch

Antara: Antara is a branded drug sold in the US and an important product in Lupin's branded portfolio. As per the available data, Lupin generates annual revenues of US$ 60 m from the sale of this drug in the US. Though the EBITDA margin of this product is not known to us, we believe that this product is not margin accretive.

The launch by Mylan is much ahead of time and thus is expected to impact Lupin's topline. It is also important to note that, Antara is a type of Fenofibrate. Fenofibrates are mainly used to treat disease pertaining to cardiovascular and used to reduce cholesterol levels in patients. Tricor is also a type of fenofibrate and is the largest selling drug (market size US$ 1 bn in US) in the fenofibrate group of drugs. The generics of Tricor have been available since the last few months; due to this Lupin's Antara was expected to face pressure in the upcoming period. The launch by Mylan will further hamper Lupin's sales; however the impact on bottom line is not expected to be much.

Fortamet: Fortamet is a branded drug and sold by Shionogi and Andrx Pharma. Fortamet is a type of metformin and is indicated to manage sugar levels in patients with type II diabetes. The annual brand sale of the Fortamet brand is US$ 125 m. Some time back, Lupin had launched Fortamet generics at risk. Lupin is still under litigation with the innovator for making the launch before patent expiry and is the only generic company selling the generics of Fortamet.

With the said settlement, Mylan will be the second generic company to launch this drug and this will impact Lupin's market share. Inspite of Mylan being the only player other than Lupin, yet the latter is expected to face decline in market share. This is because Lupin is selling its generics at risk. Now in case of an unfavorable verdict from the court, Lupin will have to pay damages incurred to the innovator for launching its generics. Therefore, generic companies launching the drugs at risk do not offer their drugs at very high discounts as normally done by the companies. The reason being, in case of any unfavorable verdict given to generic companies, their penalties are directly linked to the price erosion done by the generic company who has launched the drug at risk. Now as Mylan will enter the market it will sell its generics at much lower price in order to gain market share, as its launch is legal (launch is as per settlement). However, the same cannot be said for Lupin. Thus, this is likely to impact Lupin's market share and thus its sales.

Our View

As Mylan is among the stronger generic players in the US, its entry in two of the low competition drugs will certainly impact Lupin. While the impact on Antara will be visible from Q4FY13 onwards, the decline in revenues of Fortamet will come from 2QFY14 onwards. Thus unless Lupin ramps up its market share in other products or introduces new low competition products in the US, the decline in revenues in this segment is likely to impede the overall sales of the company.

Equitymaster requests your view! Post a comment on "Will Mylan's move impact Lupin's revenues?". Click here!

  

More Views on News

Top 5 Stocks Mutual Funds Bought and Sold in March 2021 (Sector Info)

Apr 16, 2021

A look at what India's top equity mutual funds bought and sold in March 2021.

Kotak India EQ Contra Fund: Eliminating Emotional Bias (Outside View)

Apr 16, 2021

PersonalFN's analysis on the features and performance of Kotak India EQ Contra Fund.

A Warning About Bubbles (Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Market Crash: Picture Abhi Baaki Hai? podcast (Views On News)

Apr 15, 2021

Rahul Shah on whether another big crash is likely and the ideal strategy to counter it.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On... (Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits (Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE SENSEX


Apr 16, 2021 (Close)

MARKET STATS